New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
July 22, 2014
08:11 EDTMYOSMYOS reports positive top-line clinical study results for Fortetropin
MYOS announced positive top-line results of its clinical trial designed to study the effects of Fortetropin in conjunction with modest resistance training in male subjects. The University of Tampa clinical trial was designed to analyze important body composition measurements and strength performance at two dose levels of Fortetropin over a twelve week period. The randomized, double-blind, placebo controlled trial clinically demonstrated that Fortetropin resulted in statistically significant increases in both muscle size and lean body mass in average males. The study evaluated 45 male subjects adhering to a supervised nutritional intake program and a monitored modest resistance training regimen over a period of twelve weeks. The various endpoints included skeletal muscle hypertrophy, lean body mass, fat mass and measurements of strength and power. Subjects taking Fortetropin showed significantly improved lean body mass and increased muscle size compared to placebo.
News For MYOS From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
October 16, 2014
06:36 EDTMYOSMYOS files $75M mixed securities shelf
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use